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Unruptured Brain AVMs May Benefit From Medical Management Alone
In a study of patients with unruptured brain arteriovenous malformations (AVMs), the ARUBA trial did not enroll any patients with a brain AVM >60 mm or with a Spetzler-Martin AVM grade >4.
Background: The approach to managing patients with unruptured brain arteriovenous malformations (AVMs) is uncertain. Almost 50% of diagnosed AVMs have not bled prior to diagnosis. The results of recent prospective series suggest that the subsequent bleeding risk of AVMs that have not already bled may be as low as 1%/year. Objective: To compare the risk of death and symptomatic stroke after medical management alone versus medical management with interventional therapy for an unruptured brain AVM. Design: Prospective, multicenter, parallel design, open-label randomized trial. Participants: Included patients were ≥18 years of age; had an AVM diagnosed by catheter angiography, MRI, MR angiography, CT, or CT angiography; had no evidence of bleeding of the lesion; and had an AVM that could be eradicated if assigned to that arm of the trial. Methods: Patients were randomly assigned to receive either medical management alone (therapy for seizures, headaches, and any coexisting vascular risk factor) or medical management combined with interventional therapy (neurosurgical, endovascular, radiotherapy, or combinations of these procedures). Patients were seen every 6 months for the first 2 years, then annually thereafter. The primary outcome measure was symptomatic stroke or death. The secondary outcome measure was clinical impairment at 5 years (modified Rankin scale score of ≥2).
Results:
The study was stopped prematurely after 226 patients were enrolled. Because 323 patients refused participation and 177 patients were treated outside of randomization, a potential source of bias was introduced.
Of the 226 patients enrolled, 116 received interventional therapy and 110 received medical management alone. Baseline characteristics were similar for both groups: the mean patient age was 44.5 years, approximately 41% of subjects were female, and 43% of patients had no symptoms, such as headaches or seizures, at presentation. All AVMs were <60 mm. No patients had a Spetzler-Martin AVM grade >4. The mean follow-up was 33 months. Symptomatic stroke or death occurred in 10.1% of patients receiving medical management alone and 30.7% of interventional therapy patients. At 30 months, a modified Rankin scale score of ≥2 (clinical impairment) occurred in 46.2% of interventional therapy patients and 15.1% of patients receiving medical management alone. When stratified by Spetzler-Martin grade, the highest event rates were in those with AVM grades 2 and 3.
Conclusions:
In patients with unruptured brain AVMs, medical management alone is superior to interventional therapy for the prevention of death or stroke up to 33 months. Reviewer's Comments: This trial is surrounded by substantial controversy. An editorial by Cockroft and colleagues (Stroke 2012; 43:1979 -1981 argues that ARUBA's follow-up is not long enough and that the study population does not include a broad representation of patients with brain AVMs. When counseling patients, it may be best to identify the patient to whom ARUBA most closely applies. (Reviewer-Brian Silver, MD). Family members can benefit from being present during brain death examination of their loved ones.
Background: Family members increasingly are permitted to be present during resuscitations, invasive procedures, and at the time of patients' deaths without impacting psychological stress. Concerns about family member presence during brain death examination have included disruption to care, fear of litigation, and psychological distress. Objective: To determine if family presence during brain death examination impacts family member distress. Design: Single-institution, prospective, randomized controlled trial. Methods: Subjects consisting of family members aged >17 years of patients suspected of suffering brain death in the medical intensive care unit (ICU), neurosciences ICU, trauma/surgical ICU, and pediatric ICU were asked to provide informed consent to participate in the study. Consenting subjects were randomized as family groups to be present or absent during brain death examination. Subjects completed a questionnaire measuring understanding about brain death prior to brain death examination and then again after the examination. Organ donation requests followed brain death declaration. Impact of Event Scale (IES) and General Health Questionnaire-12 (GHQ-12) surveys measured emotional and psychological impact of the brain death experience on subjects. Subjects were surveyed by telephone 1 month after brain death examination. Results: 17 of 30 families agreed to participate, and accounted for 58 subjects. In total, 38 family members of 11 patients were present during brain death examination, and 20 family members of 6 patients were not present. Understanding of brain death was similar between groups prior to examination, but better in subjects present after examination. Thirty-six of 38 subjects (94.7%) present during the examination felt that their presence helped their understanding, and 32 (84.2%) would recommend being present to others. Follow-up IES and GHQ-12 obtained in 41 subjects (71%) -24 present and 17 absentwere similar between groups. Brain death examination was not disrupted by any family member. Organ procurement was obtained in 10 of 16 potential organ donors. Of the nondonors, positive consent was obtained in 4; consent was not obtained in 1 patient with family members present and 1 with family members absent. Conclusions: Family member presence during brain death examination increases their understanding of the process without increasing emotional or psychological distress. Reviewer's Comments: This study supports the practice of allowing family members to be present during brain death examination of critically ill patients. Using the metrics assessed, these family members did not suffer adversely and had a better understanding of their loved ones' extent of illness and the processes associated with end-of-life care. There may have been some bias by the informed consenting process, and the sample size was small. Regardless, these issues are important for neurosurgeons, who encounter these events frequently. Impact on organ donation could not be determined. I will consider a family member presence approach to brain death examination. (Reviewer-N. Scott Litofsky, MD, FACS).
Background: Cervical radiculopathy is a common condition that is amenable to nonoperative treatment in most cases. Persistent and severe cases are treated with anterior cervical discectomy and fusion (ACDF). The surgical outcomes are usually favorable. Objective: To compare the efficacy of a comprehensive physical therapy program alone versus ACDF with postoperative physiotherapy for the treatment of cervical radiculopathy. Design: Prospective, randomized controlled trial. Participants/Methods: Consecutive patients were recruited into the study in 3 Swedish spine centers during a 6-year study interval. To be included in the study, patients must have been between 18 and 65 years of age, must have had radicular symptoms lasting between 8 weeks and 5 years, and must have MRI evidence of cervical stenosis in 1 or 2 levels. Patients were randomly assigned to treatment with ACDF followed by physiotherapy or physiotherapy alone. They were then followed up for 24 months. In the ACDF group, patients started physiotherapy at 3 months postoperatively after they were confirmed to be fused radiographically and clinically. The nonsurgical patients were treated with comprehensive physical therapy, including neck-specific exercises, general exercises, and pain-coping and stress management training for a minimum of 3 months. The outcomes data were collected prospectively at regular intervals for 24 months. Results: There were 31 patients in the surgical group and 32 in the nonsurgical group. The baseline sociodemographic data were similar in both groups, except that the surgical group was slightly older (4.7 years). The study outcomes showed that both groups improved significantly over time. The neck pain intensity scores (visual analog scores) and patient's global assessment were significantly better in the surgery group at 12 months but not at 24 months. There was a trend at better scores in all outcome measures in the ACDF group at the end of the study (24 months), but the differences were not statistically significant. Conclusions: ACDF combined with postoperative physiotherapy, when compared to physiotherapy alone, leads to better neck pain reduction and global assessment scores in the short term, but the difference between the groups diminishes with time. The authors acknowledge that low sample size and the crossover may have affected their results. They emphasize that physical therapy was still found to be quite successful and should be attempted prior to surgery in patients with cervical radiculopathy. Reviewer's Comments: This study definitely adds to the body of knowledge about treatment options for cervical radiculopathy. The results emphasize the importance of trying nonoperative treatments prior to surgery, but they also show that surgery may lead to faster resolution of symptoms. The study by its design would have diminished the benefits of surgical intervention due to voluntary enrollment and ability to crossover into the surgical group. (Reviewer-Vladimir Sinkov, MD).
Wear Thyroid Shields Tightly to Reduce Radiation Dose
Types and Arrangements of Thyroid Shields to Reduce Exposure of Surgeons to Ionizing Radiation During Intraoperative Use of C-Arm Fluoroscopy. Lee SY, Min E, et al: Spine 2013; 38 (November): 2108 38 (November): -2112 During intraoperative use of C-arm fluoroscopy, the use of a thyroid shield by the surgeon is most effective at reducing the radiation dose to the thyroid when worn tightly.
Background: Orthopedic surgeons are increasingly using radiation during various procedures. The most radiosensitive tissues include the thyroid, cornea, bone marrow, breasts, and gonads. While the wearing of lead shields is essentially routine, thyroid shields are sometimes omitted or worn loosely due to discomfort. Objective: To determine the radiation dose to the surgeon's thyroid during intraoperative use of C-arm fluoroscopy and the effects of different "wearing" styles of lead thyroid shields on the degree of radiation exposure.
Methods:
Phantoms were used to model a patient and a surgeon performing thoracic spine surgery. Three different ways of wearing a lead thyroid shield were modeled: worn tightly, worn loosely, and worn loosely but with a bismuth-masking agent under the lead shield and around the surgeon's neck. The latter technique is an accepted way of increasing the protection without the shield needing to be worn as tightly. These experiments were repeated using a commercially available lead-equivalent shield that is lighter than lead. Results: Wearing the thyroid shield tightly reduced the exposure to the thyroid to nearly half the value of that experienced by wearing it loosely. Use of a bismuth mask with a lead shield reduced the exposure slightly more than did either of the other 2 shield-wearing conditions without a masking layer. Use of a lead-equivalent shield was actually slightly better than lead, although it was more expensive. A thyroid shield, even when worn loosely, reduced the dose to the thyroid by >85% compared to wearing none at all. Conclusions: Thyroid shields are very helpful in reducing the radiation dose to the thyroid. They are significantly more effective when worn tightly. Use of a bismuth layer underneath the shield is an effective alternative. The lead-equivalent shields are good substitutes for lead shields.
Reviewer's Comments: The results of this useful study can help us improve the safety of surgeons in the operating room. During intraoperative use of C-arm fluoroscopy, the use of a thyroid shield by the surgeon should be routine, and it should be worn tightly. Several spine deformity surgeons have been affected by thyroid cancer, and it behooves all of us to take protective measures and wear the thyroid shield tightly when necessary. (Reviewer-Paul D. Sponseller, MS, MD, MBA).
